Gastrointestinal adverse events of semaglutide in patients with overweight or obesity

被引：1
作者：
Tariq, Muhammad Ali [1 ,4 ]
Amin, Hamza [2 ]
Shurjeel, Qazi [2 ]
Gang, Ahmed [3 ]
Mohiuddin, Ashar [1 ]
机构：
[1] Dow Int Med Coll, Dow Univ Hosp, Karachi, Pakistan
[2] Dow Univ Hlth Sci, Ruth KM Pfau Civil Hosp, Karachi, Pakistan
[3] Jinnah Postgrad Med Ctr, Karachi, Pakistan
[4] Dow Int Med Coll, Dow Univ Hosp, Dept Med, Gulzar E Hijri Scheme 33,Suparco Rd, Karachi, Pakistan
来源：
EUROPEAN JOURNAL OF INTERNAL MEDICINE | 2022年 / 106卷
关键词：
D O I：
10.1016/j.ejim.2022.08.015
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：138 / 139
页数：2
相关论文
共 8 条
  • [1] Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials
    Ahren, Bo
    Atkin, Stephen L.
    Charpentier, Guillaume
    Warren, Mark L.
    Wilding, John P. H.
    Birch, Sune
    Holst, Anders Gaarsdal
    Leiter, Lawrence A.
    [J]. DIABETES OBESITY & METABOLISM, 2018, 20 (09) : 2210 - 2219
  • [2] Corrination of a GLP-1 Receptor Agonist for Glycemic Control without Emesis
    Borner, Tito
    Workinger, Jayme L.
    Tinsley, Ian C.
    Fortin, Samantha M.
    Stein, Lauren M.
    Chepurny, Oleg G.
    Holz, George G.
    Wierzba, Aleksandra J.
    Gryko, Dorota
    Nexo, Ebba
    Shaulson, Evan D.
    Bamezai, Ankur
    Rodriguez Da Silva, Valentina A.
    De Jonghe, Bart C.
    Hayes, Matthew R.
    Doyle, Robert P.
    [J]. CELL REPORTS, 2020, 31 (11):
  • [3] ClinicalTrials.gov, STEP 5 TRIAL
  • [4] Pharmacological profile of once-weekly injectable semaglutide for chronic weight management
    Lau, David C. W.
    Batterham, Rachel L.
    le Roux, Carel W.
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2022, 15 (03) : 251 - 268
  • [5] Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Shi, Fang-Hong
    Li, Hao
    Cui, Min
    Zhang, Zai-Li
    Gu, Zhi-Chun
    Liu, Xiao-Yan
    [J]. FRONTIERS IN PHARMACOLOGY, 2018, 9
  • [6] Wegovy (semaglutide): a new weight loss drug for chronic weight management
    Singh, Gurdeep
    Krauthamer, Matthew
    Bjalme-Evans, Meghan
    [J]. JOURNAL OF INVESTIGATIVE MEDICINE, 2022, 70 (01) : 5 - 13
  • [7] Gastrointestinal Adverse Events of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
    Sun, Feng
    Chai, Sanbao
    Yu, Kai
    Quan, Xiaochi
    Yang, Zhirong
    Wu, Shanshan
    Zhang, Yuan
    Ji, Linong
    Wang, Jun
    Shi, Luwen
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2015, 17 (01) : 35 - 42
  • [8] Once-Weekly Semaglutide in Adults with Overweight or Obesity
    Wilding, John P. H.
    Batterham, Rachel L.
    Calanna, Salvatore
    Davies, Melanie
    Van Gaal, Luc F.
    Lingvay, Ildiko
    McGowan, Barbara M.
    Rosenstock, Julio
    Tran, Marie T. D.
    Wadden, Thomas A.
    Wharton, Sean
    Yokote, Koutaro
    Zeuthen, Niels
    Kushner, Robert F.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (11) : 989 - 1002
1